Exelixis vs Neurocrine Biosciences: revenue, profit, margins and growth compared
Exelixis brought in $2.3B of revenue in fiscal 2025, Neurocrine Biosciences $2.9B in fiscal 2025. Revenue changed by +7.0% at Exelixis and +21.4% at Neurocrine Biosciences on the year before, so Neurocrine Biosciences grew faster. Exelixis kept 33.7% of its revenue as net profit, Neurocrine Biosciences 16.7%. Free cash flow was $875.8M at Exelixis and $748.7M at Neurocrine Biosciences.
Fiscal years as each company reports them; the two may end in different months.
Questions about Exelixis and Neurocrine Biosciences
Which is bigger by revenue, Exelixis or Neurocrine Biosciences?
Neurocrine Biosciences is bigger by revenue: $2.9B in fiscal 2025, against $2.3B for Exelixis in fiscal 2025.
Which keeps more of its revenue as profit, Exelixis or Neurocrine Biosciences?
Exelixis had a net margin of 33.7% in fiscal 2025; Neurocrine Biosciences had 16.7% in fiscal 2025.
Which grew revenue faster, Exelixis or Neurocrine Biosciences?
In their latest fiscal years revenue changed by +7.0% at Exelixis and +21.4% at Neurocrine Biosciences.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.